Skip to content

A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy

A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02245334
Enrollment
1578
Registered
2014-09-19
Start date
2014-10-31
Completion date
2015-12-31
Last updated
2014-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Misadventure During Aspirating Needle Biopsy, Prostatic Diseases

Brief summary

To assess the effect of povidone-iodine on infectious complication rate caused by transrectal prostate biopsy

Detailed description

the effect of povidone-iodine on infectious complication rate caused by transrectal prostate biopsy

Interventions

DRUGPovidone-Iodine

1 pill per biopsy

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* who undergo transrectal prostate biopsy

Exclusion criteria

* patients who refuse to be included, patients who have hypersensitivity to iodine, patients who have abnormal thyroid function, patients who do not visit follow-up, patients who have received prior radioactive-iodine therapy

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with febrile infection1 weekconsider fever over 38 degree celsius or admission due to fever

Secondary

MeasureTime frameDescription
voiding questionnaire1-2 weekcheck International Prostate Symptom Score (IPSS)
sexual function questionnaire1-2 weekInternational Index of Erectile Function-5 (IIEF-5)
quality of life questionnaire1-2 weekEuropean Organization for Research and Treatment fo Cancer (EORTC) Quality of life Questionnaire (QLQ)-C30 questionnaire

Countries

South Korea

Contacts

Primary ContactSangchul Lee
uromedi@naver.com+82-31-787-7345

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026